Premier Anti Aging : Summary of Financial Results for the third quarter 2022

0
195








Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 13, 2022

Consolidated Financial Results

for the Nine Months Ended April 30, 2022

(Under Japanese GAAP)

Company name:

Premier Anti-Aging Co., Ltd.

Listing:

Tokyo Stock Exchange

Securities code:

4934

URL:

https://www.p-antiaging.co.jp/

Representative:

Kiyoshi Matsuura, President and Representative Director

Inquiries:

Takahiro Toya, Managing Executive Officer and Director

Telephone:

+81-3-3502-2020

Scheduled date to file quarterly securities report:

June 13, 2022

Scheduled date to commence dividend payments:

Preparation of supplementary material on quarterly financial results: Yes

Holding of quarterly financial results briefing:

Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended April 30, 2022 (from August 1, 2021 to April 30, 2022)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

Net sales

Operating profit

Ordinary profit

Profit attributable to

owners of the parent

Nine months ended

Millions of yen

%

Millions of yen

%

Millions of yen

%

Millions of yen

%

April 30, 2022

25,896

9.0

1,957

(55.8)

2,141

(51.5)

1,222

(56.8)

April 30, 2021

23,766

4,428

4,416

2,827

Note: Comprehensive income

For the nine months ended April 30, 2022:

1,248 million yen

[(55.9)%]

For the nine months ended April 30, 2021:

2,827 million yen

[ – ]

Earnings per share

Diluted earnings

per share

Nine months ended

Yen

Yen

April 30, 2022

140.18

139.97

April 30, 2021

333.15

332.65

Note: 1. Since the consolidated financial statements are prepared from the second quarter of the fiscal year ended July 31, 2021, the percentage change from the same period of the previous year for the third quarter of the fiscal year ended July 31, 2021 is not shown.

    1. Diluted earnings per share for the third quarter of the fiscal year ended July 31, 2021 is calculated based on the average share price from the initial listing date to the end of the third quarter of the fiscal year ended July 31, 2021, since the Company was listed on the Tokyo Stock Exchange Mothers section on October 28, 2020.
    2. On August 29, 2020, a 20-for-1 stock split of shares of common stock was conducted. Therefore, earnings per share and diluted earnings per share are calculated on the assumption that the stock split was conducted at the beginning of the fiscal year ended July 31, 2021.
    3. The “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and others were applied from the beginning of the first quarter of the current fiscal year. The figures for the third quarter of the fiscal year ending July 31, 2022 have been retroactively adopted to the above accounting standards.
  1. Consolidated financial position

Total assets

Net assets

Equity-to-asset ratio

As of

Millions of yen

Millions of yen

%

April 30, 2022

12,755

8,142

63.8

July 31, 2021

13,071

6,903

52.8

Reference: Total shareholders’ equity

As of April 30, 2022:

8,142 million yen

As of July 31, 2021:

6,903 million yen

Note: The “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and others were applied from the beginning of the first quarter of the current fiscal year. The figures for the third quarter of the fiscal year ending July 31, 2022 have been retroactively adopted to the above accounting standards.

2. Cash dividends

Annual dividends per share

First quarter-end

Second quarter-end

Third quarter-end

Fiscal year-end

Total

Yen

Yen

Yen

Yen

Yen

Fiscal year ended

0.00

0.00

0.00

July 31, 2021

Fiscal year ending

0.00

July 31, 2022

Fiscal year ending

July 31, 2022

0.00

0.00

(Forecast)

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated earnings forecasts for the fiscal year ending July 31, 2022 (from August 1, 2021 to July 31, 2022)

(Percentages indicate year-on-year changes.)

Net sales

Operating profit

Ordinary profit

Profit attributable to

Earnings per share

owners of the parent

Fiscal year ending

Millions of yen

%

Millions of yen

%

Millions of yen

%

Millions of yen

%

Yen

July 31, 2022

34,000

2,300

2,500

1,380

158.25

Note: 1. Revisions to the earnings forecasts most recently announced: Yes

  • 2. The “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and others were applied from the beginning of the first quarter of the current fiscal year. The figures for the above consolidated earnings forecasts are after the application of the aforementioned accounting standards. As a result, the percentage change from the actual results before the application of these standards, etc., is not shown.

  • Notes
  1. Changes in significant subsidiaries during the current period (changes in specified subsidiaries resulting in change in scope of consolidation): None
  2. Adoption of accounting treatment unique to the preparation of quarterly consolidated financial statements: Yes
  3. Changes in accounting policies, changes in accounting estimates, and restatements
    1. Changes in accounting policies associated with the revision of the accounting standard: Yes
    2. Changes in accounting policies other than those stated above: Yes
    3. Changes in accounting estimates: None
    4. Restatements: None

(Note) For details, please refer to “2. Consolidated financial statements and major notes (3) Notes to consolidated financial statements (Changes in accounting policies)” on page 7 of the attached document.

  1. Number of shares outstanding (common shares)
  1. Total number of shares outstanding at the end of the period (including treasury shares)

3Q of FY2022

8,720,543 shares

FY2021

8,720,000 shares

  1. Number of treasury shares at the end of the period

3Q of FY2022

89 shares

FY2021

89 shares

  1. Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

3Q of FY2022

8,720,216 shares

3Q of FY2021

8,488,045 shares

(Note) On August 29, 2020, a 20-for-1 stock split of shares of common stock was conducted. Therefore, the number of shares outstanding at the end of the period and the average number of shares during the period were calculated assuming that the stock split was conducted at the beginning of the fiscal year ended July 31, 2021.

  • The quarterly financial results are not subject to quarterly review by a certified public accountant or an auditing firm.
  • Explanation on the proper use of earnings forecasts and other special matters

The forward-looking statements in this document are based on information currently available to the Company and certain assumptions that the Company deems reasonable and are not intended as a promise by the Company that they will be achieved. Actual results may differ from these forecasts due to a variety of factors. For assumptions used in forecasting earnings and precautions regarding the use of earnings forecasts, please refer to “1. Qualitative information for the third quarter of the fiscal year ending July 31, 2022 (3) Explanation of consolidated earnings forecasts and other forward-looking information” on page 3 of the attached document.

Attached Materials

Contents

1 Qualitative information for the third quarter of the fiscal year ending July 31, 2022 ……………………..

2

(1) Explanation on the consolidated financial results ……………………………………………………

2

  1. Explanation on the consolidated financial position ………………………………………………….. 2
  2. Explanation on consolidated earnings forecasts and other forward-looking information …………….. 3

2. Consolidated financial statements and major notes ……………………………………………………….. 4

  1. Consolidated balance sheet …………………………………………………………………………… 4
  2. Consolidated statement of income and consolidated statement of comprehensive income …………. 5 Consolidated statement of income
    Nine months ended April 30, 2022 …………………………………………………………………. 5 Consolidated statement of comprehensive income
    Nine months ended April 30, 2022 …………………………………………………………………. 6
  3. Notes to the consolidated financial statements ………………………………………………………. 7 (Notes on going concern assumption) ……………………………………………………………….. 7 (Notes in the event of significant changes in the amount of shareholders’ equity) ………………….. 7 (Application of accounting treatment unique to the preparation of
    quarterly consolidated financial statements) …………………………………………………………. 7

(Changes in accounting policies) ……………………………………………………………………..

7

(Additional information) ……………………………………………………………………………..

8

(Segment information and others) ……………………………………………………………………

8

1

1. Qualitative information for the third quarter of the fiscal year ending July 31, 2022

  1. Explanation on the consolidated financial results

During the first nine months of the current fiscal year, the Japanese economy continued to face a highly uncertain environment due to soaring global raw material prices, escalating tensions in Ukraine, and sharp exchange rate fluctuations, although the long-implemented action restrictions to prevent the spread of COVID-19 were finally eased in late March and there were signs of normalization in economic activities.

Under these circumstances, Premier Anti-Aging Co., Ltd. (hereinafter called the “Company”) and its consolidated subsidiaries (hereinafter called the “Group”) have been committed to “being unique” since its establishment and have promoted the expansion of anti-aging related business by launching multiple brands in new categories by combining our strengths in “product planning capability” and “marketing capability” with our ” subscription sales model”.

In the “DUO” brand, the competitive environment intensified due to the introduction of a series of inexpensive balm products by competitors, in addition to the slowdown of the record-setting “DUO The Cleansing Balm Black Repair.” Meanwhile, the “CANADEL” brand, which is being nurtured as the second earnings pillar following the “DUO” brand, achieved a record high single-month sales in April, surpassing 700 million yen, thanks to increased sales mainly of the high-priced “CANADEL Premier Zero” and “CANADEL Barrier Fix”, a quasi-drug containing niacinamide, which is effective against skin spots and wrinkles, launched in April, under the strategy of “offering all-in-one cosmetics for younger customers.” In late March, the Company horizontally deployed the brand nurturing know-how gained from “DUO” and “CANADEL” to launch a new brand, “clayence,” targeting gray hair in the younger generation. The “clayence” brand has surpassed 10,000 new weekly acquisitions in the first week since its launch, and we have high expectations of this brand to grow as a new revenue pillar.

The number of new subscription sales customers acquired in mail-order sales remained at a high level, with a total of approximately 120,000 new acquisitions for all brands. What is distinctive compared to the past is the progress in diversification from “DUO” centered acquisitions to acquisitions of multiple brands, and the stabilization of business is steadily advancing.

As a result of the above activities, net sales for the period amounted to 25,896,891 thousand yen (up 9.0% year-on- year), operating profit was 1,957,490 thousand yen (down 55.8% year-on-year), ordinary profit was 2,141,632 thousand yen (down 51.5% year-on-year), and profit attributable to owners of the parent was 1,222,406 thousand yen (down 56.8% year-on-year).of the above activities, net sales, operating profit, ordinary profit, and profit attributable to owners of the parent for the third quarter of the current fiscal year totaled 25,896,891 thousand yen, 1,957.490 thousand yen, 2,141,632 thousand yen, and 1,222,406 thousand yen, respectively.

As the Group consists of a single business segment of manufacturing and sales of cosmetics, the description by segment is omitted.

  1. Explanation on the consolidated financial position

Assets, liabilities and net assets at the end of the third quarter of the current fiscal year were as follows. (Assets)

Total assets at the end of the third quarter of the current consolidated fiscal year decreased 316,265 thousand yen from the end of the previous consolidated fiscal year to 12,755,067 thousand yen.

Current assets decreased 551,289 thousand yen from the end of the previous fiscal year to 11,928,590 thousand yen. This was mainly due to a decrease of 2,507,477 thousand yen in cash and cash equivalents, a decrease of 656,493 thousand yen in accounts receivable, an increase of 1,729,665 thousand yen in products, an increase of 429,090 thousand yen in raw materials and supplies, and an increase of 295,222 thousand yen in prepaid expenses included in “Others” under current assets.

Non-current assets increased 235,023 thousand yen from the end of the previous fiscal year to 826,476 thousand yen. This was mainly due to a 124,952 thousand yen increase in software included in intangible assets and an increase of 160,514 thousand yen in lease deposits included in investments and other assets.

(Liabilities)

Total liabilities at the end of the third quarter decreased by 1,555,395 thousand yen from the end of the previous fiscal year to 4,612,819 thousand yen.

2

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Premier Antiaging Co. Ltd. published this content on 13 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 June 2022 06:32:10 UTC.

Publicnow 2022

All news about PREMIER ANTI-AGING CO., LTD.

Sales 2022 37 767 M
281 M
281 M
Net income 2022 3 219 M
24,0 M
24,0 M
Net cash 2022 7 071 M
52,7 M
52,7 M
P/E ratio 2022 11,0x
Yield 2022
Capitalization 35 274 M
263 M
263 M
EV / Sales 2022 0,75x
EV / Sales 2023 0,61x
Nbr of Employees 152
Free-Float 30,2%

Chart PREMIER ANTI-AGING CO., LTD.



Duration :


Period :




Premier Anti-Aging Co., Ltd. Technical Analysis Chart | MarketScreener

Technical analysis trends PREMIER ANTI-AGING CO., LTD.

Short Term Mid-Term Long Term
Trends Bullish Bearish Bearish



Income Statement Evolution

Sell

Buy

Mean consensus BUY
Number of Analysts 2
Last Close Price 4 045,00 JPY
Average target price 5 060,00 JPY
Spread / Average Target 25,1%




Source link